About Us
Targeting Inflammatory GI Disorders
Meet our team
We leverage an executive team and board of directors and advisors with a track record of creating lasting impact in healthcare innovation.
Krishnan Nandabalan, Ph.D.
Chairman, President & CEO
Salvatore Alesci, M.D., Ph.D.
Chief Scientific Officer
Steve Okada, M.D.
Chief Medical Officer
Aman Kant
Chief Business Officer
Michael Aiello, CPA
Chief Financial Officer
Patricia Spera, Ph.D.
VP, Clinical Operations
Anita Ganjoo, Ph.D.
VP, External Communications
Krishnan Nandabalan, Ph.D.
Chairman, President & CEO
Salvatore Alesci, M.D., Ph.D.
Chief Scientific Officer
Steve Okada, M.D.
Chief Medical Officer
Aman Kant
Chief Business Officer
Michael Aiello, CPA
Chief Financial Officer
Patricia Spera, Ph.D.
VP, Clinical Operations
Anita Ganjoo, Ph.D.
VP, External Communications
Krishnan Nandabalan, Ph.D.
Chairman of Board
Invea Therapeutics
Demetrios Kydonieus, MBA
President
R-Pharm
Jonathan Zalevsky, Ph.D.
SVP, Research & CSO
Nektar Therapeutics
Kerrie Brady, MBA, MS
CEO
OcuTerra
Vimal Mehta, Ph.D.
CEO & Founder
BioXcel Therapeutics
Jason Fenton
Head of Healthcare Capital Markets
Oppenheimer & Co. Inc.
Krishnan Nandabalan, Ph.D.
Chairman of Board
Invea Therapeutics
Demetrios Kydonieus, MBA
President
R-Pharm
Jonathan Zalevsky, Ph.D.
SVP, Research & CSO
Nektar Therapeutics
Kerrie Brady, MBA, MS
CEO
OcuTerra
Vimal Mehta, Ph.D.
CEO & Founder
BioXcel Therapeutics
Jason Fenton
Head of Healthcare Capital Markets
Oppenheimer & Co. Inc.
Debra Silberg, M.D., Ph.D.
Donna Griebel, M.D.
Evan S. Dellon, M.D., MPH
Heather Francis, Ph.D.
Joshua B. Wechsler, M.D., MSCI
Silvio Danese, M.D., Ph.D.
